Organisation paid for research Program year 2025 Source: CMS Open Payments

Floridian Clinical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$2,691,136

131 payments

Through program year 2025, Floridian Clinical Research, LLC is reported as receiving $2,691,136 in research payments, across 131 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $1,453,185 20
2024 Research $10,698 5
2023 Research $5,239 1
2021 Research $643,066 12
2020 Research $559,189 24
2019 Research $19,761 69

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $1,406,647 3 payments
  2. Merck Sharp & Dohme Corporation $688,112 35 payments
  3. AstraZeneca Pharmaceuticals LP $519,382 2 payments
  4. CSL Behring $57,235 22 payments
  5. AbbVie, Inc. $18,241 2 payments
  6. Novo Nordisk AS $1,519 67 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AMG 133 in Participants with Normal Renal Function and Participants with Various Degrees of Renal Impairment $1,387,854 1 payment
  2. A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) $393,875 1 payment
  3. A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis $288,566 3 payments
  4. Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine,Islatravir Once-Daily in HIV-1 Infected Treatment-Na Participants $144,506 4 payments
  5. A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide MK-6024 in Individuals With Nonalcoholic Fatty Liver Disease $129,492 3 payments
  6. A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $125,507 1 payment
  7. A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Participants with End Stage Renal Disease Receiving Hemodialysis. $77,241 2 payments
  8. A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis $57,235 22 payments
  9. A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Avacopan in Subjects With Normal Renal Function and Subjects With End-Stage Renal Disease (ESRD) Requiring Hemodialysis $18,793 2 payments
  10. M18-891 $18,241 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record